Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord

Nature Medicine

Volumn 6, Issue 5, 2000, Pages 521-528

  Honore, Prisca ^a,b   Luger, Nancy M ^a,b   Sabino, Mary Ann C ^a,b   Schwei, Matthew J ^a,b   Rogers, Scott D ^a,b   Mach, David B ^a,b   O'Keefe, Patrick F ^a   Ramnaraine, Margaret L ^a   Clohisy, Denis R ^a   Mantyh, Patrick W ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE CANCER; BONE DESTRUCTION; BONE PAIN; CANCER MODEL; CELL DENSITY; CONTROLLED STUDY; HISTOPATHOLOGY; MOUSE; NEUROCHEMISTRY; NONHUMAN; ONCOGENE C FOS; OSTEOCLAST; PRIORITY JOURNAL; QUALITY OF LIFE; SARCOMA CELL; SPINAL CORD;

ANIMALS; ASTROCYTES; BEHAVIOR, ANIMAL; BONE DEMINERALIZATION, PATHOLOGIC; GLYCOPROTEINS; HINDLIMB; MALE; MICE; MICE, INBRED C3H; OSTEOCLASTS; OSTEOPROTEGERIN; OSTEOSARCOMA; PAIN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SARCOMA, EXPERIMENTAL; SPINAL CORD;

ANIMALIA;

EID: 0034105966     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/74999     Document Type: Article

References (50)

1. Banning, A., Sjogren, P. & Henriksen, H. Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain 45, 45-48 (1991).
2. Coleman, R.E. et al. A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. Eur. J. Cancer 34, 820-824 (1998).
3. Coleman, R.E. How can we improve the treatment of bone metastases further? Curr. Opin. Oncol. 10, 57-13 (1998).
4. Coleman, R.E. & Rubens, R.D. The clinical course of bone metastases from breast cancer. Br. J. Cancer 55, 61-66 (1987).
5. Rosier, R. Bone pain. Am. J. Hospice Palliative Care 9, 37 (1992).
6. Lipton, A. Bisphosphonates and breast carcinoma. Cancer 80, 1668-1673 (1997).
7. Fulfaro, F., Casuccio, A., Ticozzi, C. & Ripamonti, C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 78, 157-169 (1998).
8. Mercadante, S. & Arcuri, E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat. Rev. 24, 425-432 (1998).
9. Mercadante, S. Malignant bone pain: pathophysiology and treatment. Pain 69, 1-18 (1997).
10. Portenoy, R.K., Payne, D. & Jacobsen, P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81, 1 29-134 (1999).
11. Payne, R. Practice guidelines for cancer pain therapy. Issues pertinent to the revision of national guidelines. Oncology 12, 169-175 (1998).
12. Payne, R. Mechanisms and management of bone pain. Cancer 80, 1608-1613 (1997).
13. Clohisy, D.R. & Ramnaraine, M.L. Osteoclasts are required for bone tumors to grow and destroy bone. J. Orthopaed. Res. 16, 660-666 (1998).
14. Kong, Y.Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 (1999).
15. Simonet, W.S. et al. Osteoprotegerin - a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319 (1997).
16. Lacey, D.L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998).
17. Schwei, M.J. et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J. Neurosci. 19, 10886-10897 (1999).
18. Honore, P., Chapman, V., Buritova, J. & Besson, J.M. To what extent do spinal interactions between an α-2 adrenoceptor agonist and a mu opioid agonist influence noxiously evoked c-Fos expression in the rat - a pharmacological study. J. Pharmocol. Exp.Ther. 278, 393-403 (1996).
19. Hunt, S.P., Pini, A. & Evan, C. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature 328, 632-634 (1987).
20. Doyle, C.A. & Hunt, S.P. Substance P receptor (neurokinin-1)-expressing neurons in lamina 1 of the spinal cord encode for the intensity of noxious stimulation: a c-Fos study in rat. Neuroscience 89, 17-28 (1999).
21. Woolf, C.J. et al. Towards a mechanism-based classification of pain. Pain 77, 227-229 (1998).
22. Kostenuik, P.J., Morony, S., Capparelli, C., Lacey, D.L. & Dunstan, C.R. Comparison of the inhibitory effects of osteoprotegerin and of APD on PTHrP-mediated hypercalcemia and bone remodeling. J. Bone Miner. Res. 14, S166 (1999).
23. Josien, R., Wong, B.R., Hong-Li, L., Steinman, R.M. & Choi, Y. TRANCE, a TNF family member is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J. Immunol. 162, 2562-2568 (1999).
24. Delaisse, J.-M. & Vaes, C. in Biology and physiology of the osteoclast (eds. Rifkin, B. R. & Gay, C. V.) 289-314 (CRC, Ann Arbor, 1992).
25. Olson, T.H., Riedl, M.S., Vulchanova, L., Ortiz-Gonzalez, X.R. & Elde, R. An acid sensing ion channel (ASIC) localizes to small primary afferent neurons in rats. Neuroreport 9, 1109-1113 (1998).
26. Sorkin, L.S., Xiao, W.H., Wagner, R. & Myers, R.R. Tumour necrosis factor-α induces ectopic activity in nociceptive primary afferent fibres. Neuroscience 81, 255-262 (1997).
27. Tonussi, C.R. & Ferreira, S.H. Tumour necrosis factor-α mediates carrageenin-induced knee-joint incapacitation and also triggers overt nociception in previously inflamed rat knee-joints. Pain 82, 81-87 (1999).
28. O'Connell, J.X., Nanthakumar, S.S., Nielsen, G.P. & Rosenberg, A.E. Osteoid osteoma: the uniquely innervated bone tumor. Modern Pathol. 11, 175-180 (1998).
29. Bjurholm, A., Kreicbergs, A., Brodin, E. & Schultzberg, M. Substance P- and CGRP-immunoreactive nerves in bone. Peptides 9, 165-171 (1988).
30. Hill, E.L. & Elde, R. Distribution of CGRP-, VIP-, DβH-, SP-, and NPY-immunoreactive nerves in the periosteum of the rat. Cell Tissue Res. 264, 469-480 (1991).
31. Tabarowski, Z., Gibson-Berry, K. & Felten, S. Y. Noradrenergic and peptidergic innervation of the mouse femur bone marrow. Acta Histochemica 98, 453-457 (1996).
32. Goni, M.H. & Tolls, G. Hypercalcemia of cancer: an update. Anticancer Res. 13, 1155-1160 (1993).
33. Suzuki, K. & Yamada, S. Ascites sarcoma 180, a tumor associated with hypercalcemia, secretes potent bone-resorbing factors including transforming growth factor alpha, interleukin-1 alpha and interleukin-6. Bone Mineral 27, 219-233 (1994).
34. Watkins, L.R. et al. Characterization of cytokine-induced hyperalgesia. Brain Res. 654, 15-26 (1994).
35. Safieh-Garabedian, B., Poole, S., Allchorne, A., Winter, J. & Woolf, C.J. Contribution of interleukin-1β to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br. J. Pharmacol. 115, 1265-1275 (1995).
36. Woolf, C.J., Allchorne, A., Safieh-Garabedian, B. & Poole, S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor α. Br. J. Pharmacol. 121, 417-424 (1997).
37. Draisci, G., Kajander, K.C., Dubner, R., Bennett, G.J. & Iadarola, M.J. Up-regulation of opioid gene expression in spinal cord evoked by experimental nerve injuries and inflammation. Brain Res. 560, 186-192 (1991).
38. Ruda, M.A., Iadarola, M.J., Cohen, L.V. & Young, W.S. d. In situ hybridization histochemistry and immunocytochemistry reveal an increase in spinal dynorphin biosynthesis in a rat model of peripheral inflammation and hyperalgesia. Proc. Natl. Acad. Sci. USA 85, 622-626 (1988).
39. Colburn, R.W. et al. Dissociation of microglial activation and neuropathic pain behaviors following peripheral nerve injury in the rat. J. Neuroimmunol. 79, 163-175 (1997).
40. Colburn, R.W., Rickman, A.J. & DeLeo, J.A. The effect of site and type of nerve injury on spinal glial activation and neuropathic pain behavior. Exp. Neurol. 157, 289-304 (1999).
41. Honore, P. et al. Spinal substance P receptor expression and internalization in acute, short-term, and long-term inflammatory pain states. J. Neurosci. 19, 7670-7678 (1999).
42. Cathetine, G., Le Guen, S., Honore, P. & Besson, J.M. Are there long-term changes in the basal or evoked Fos expression in the dorsal horn of the spinal cord of the mononeuropathic rat? Pain 80, 347-357 (1999).
43. Abbadie, C., Trafton, J., Liu, H., Mantyh, P.W. & Basbaum, A.I. Inflammation increases the distribution of dorsal horn neurons that internalize the neurokinin-1 receptor in response to noxious and non-noxious stimulation. J. Neurosci. 17, 8049-8060 (1997).
44. Abbadie, C. & Besson, J.-M. c-fos expression in rat lumbar spinal cord following peripheral stimulation in adjuvant-induced arthritis and in normal rats. Brain Res. 607, 195-204 (1993).
45. Bekker, P.J., Holloway, D., Nakanishi, A., Arrighi, H.M. & Dunstan, C.R. Osteoprotegerin (OPG) has potent and sustained anti-resoptive activity in post-menopausal women. J. Bone Mineral Res. 14, S180 (1999).
46. Kong, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402, 304-309 (1999).
47. Mantyh, P.W. et al. Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. Science 268, 1629-1632 (1995).
48. Mantyh, P.W. et al. Rapid endocytosis of a G protein-coupled receptor: substance P evoked internalization of its receptor in the rat striatum in vivo. Proc. Natl. Acad. Sci. USA 92, 2622-2626 (1995).
49. Mantyh, P.W. et al. Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. Science 278, 275-279 (1997).
50. Molander, C., Xu, Q. & Grant, G. The cytoarchitectonic organization of the spinal cord in the rat: I. The lower thoracic and lumbosacral cord. J. Comp. Neurol. 230, 133-141 (1984).